^
    Back
    Association details:
    Biomarker:SETD2 mutation
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    SUO 2020
    Title:

    Associating Specific Somatic Mutations with Immune Infiltration Patterns in Metastatic Clear Cell Renal Cell Carcinoma

    Published date:
    11/20/2020
    Excerpt:
    On Cox multivariable regression analysis, patients with SETD2 mutations had significantly worse overall survival (p<0.01) and survival following immunotherapy treatment (p<0.01).